Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Affiliations

• ¹ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
• ² Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
• ³ Hematology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
• ⁴ Institute for Biomedical Technologies, National Research Council, Milan, Italy.
• ⁵ Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
• ⁶ Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
• ⁷ Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
• ⁸ Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
• ⁹ Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• ¹⁰ Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
• ¹¹ CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France and CHU de Nantes, Nantes, France.
• ¹² Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France.
• ¹³ Boston Veterans Administration Healthcare System, West Roxbury, MA, USA.